The submission of an IND application is a significant step in the drug development process. If the application is approved, it could potentially lead to a positive impact on Alzamend Neuro's stock as it would allow the company to proceed with its Phase IIA clinical trial. This could be perceived positively by investors as it indicates progress in the company's drug development efforts.